SEC recommendation in accordance with guidelines: Biocon Biologics

The company said its product approvals are backed by science and clinical data

SAT stays Biocon insider trading order

The company said it condemns all acts of corruption and bribery and is cooperating with the investigating agency.

Biocon Biologics not only denied allegations of bribery, but said that the rationale for waiving phase-3 clinical trials for its Insulin Aspart injection was based on Indian regulatory guidance.

The company

Also Read

CBI books GAIL's marketing head E S Ranganathan in bribery case

Senior GAIL exec arrested, accused of taking bribes in petrochemicals sale

R&D expenditure will rise in the coming quarters: Biocon Biologics MD

Biocon Biologics acquires Viatris' biosimilars business in $3.3 bn deal

Biocon Biologics to go for IPO in 18-24 months: Kiran Mazumdar-Shaw

Corp governance focus must for building world-class cos: Sequoia's Anandan

Mulling smaller stores in other cities to expand India biz: IKEA chief

Jain Irrigation to merge international biz with Temasek-backed Rivulis

PVR, Inox get SEBI nod for merger to create India's largest multiplex chain

IG International, Esquire Corrugation form JV for fresh produce packaging

First Published: Jun 22 2022 | 1:15 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to